文献速递甲状腺疾病

分化型甲状腺癌放射性碘治疗吸收剂量与疗效的系统综述

A Systematic Review of Absorbed Doses and Response in Patients Treated with Radioiodine for Differentiated Thyroid Cancer.
PubMed 文献 · Thyroid · 2025-11-24

该系统综述与荟萃分析检索截至2025年8月22日的文献,纳入18项报告分化型甲状腺癌患者接受Na[131I]I治疗后靶灶吸收剂量与成功结局比例的研究。甲状腺残留消融成功率60%–100%,转移灶成功率43%–58%;残留吸收剂量≥300 Gy者成功率78%–96%,转移灶≥80 Gy者成功率46%–98%。综述认为尚未确立明确的吸收剂量-效应关系。

要点

  • 甲状腺残留消融成功率60%–100%,转移灶成功率43%–58%。
  • 残留吸收剂量≥300 Gy成功率78%–96%,转移灶≥80 Gy成功率46%–98%。
  • 剂量学方法与随访标准缺乏标准化阻碍剂量-效应关系确立。

核心结论

  • 个别研究显示Na[131I]I吸收剂量对分化型甲状腺癌重要,但本综述未确立明确的吸收剂量-效应关系。
  • 需大规模观察性前瞻研究确定个体化治疗所需吸收剂量。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Web of Science和OVID MEDLINE截至2025年8月22日的文献。
  • 共识别3723项研究,18项符合纳入标准,纳入患者数4至509例。
  • 研究注册于PROSPERO(CRD42024554956)。

主要发现

  • 甲状腺残留消融的报道成功率范围为60%至100%。
  • 转移性病灶患者的成功率较低,为43%–58%。
  • 甲状腺残留吸收剂量≥300 Gy者成功率78%–96%。
  • 转移灶吸收剂量≥80 Gy者成功率46%–98%。

关键数值与推荐

  • 甲状腺残留消融成功率为60%–100%。
  • 转移性病灶成功率为43%–58%。
  • 甲状腺残留吸收剂量≥300 Gy时成功率78%–96%。
  • 转移灶吸收剂量≥80 Gy时成功率46%–98%。

临床怎么用

  • 解读放射性碘疗效时应关注靶灶吸收剂量,但现有证据尚不足以据此设定统一剂量阈值。
  • 临床实施剂量学指导治疗时需注意各研究剂量学方法与成功标准不统一。

局限性

  • 剂量学方法缺乏标准化。
  • 随访标准不统一,掩盖了剂量-效应关系。
  • 纳入研究患者数范围4至509例,样本量差异大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of patients with thyroid cancer with Na[131I]I is routinely performed with empirical activity levels. Treatment success may be expected to correlate with the absorbed doses delivered to targets (thyroid remnants or metastatic lesions), but no systematic review or meta-analysis of absorbed dose-effect relationships has yet been performed. METHODS: A systematic review and meta-analysis of reports published before August 22, 2025, was performed using PubMed, Web of Science, and OVID MEDLINE. Studies were included if they reported the proportion of patients achieving successful outcome as defined in individual publications and the absorbed doses delivered to targets. The study is registered with PROSPERO (CRD42024554956). RESULTS: In total, 3723 studies were identified of which 18 were eligible for analysis. Number of patients in the included studies ranged from 4 to 509. For patients treated with Na[131I]I for thyroid remnant ablation, the reported success rates ranged from 60% to 100%, while lower success rates of 43-58% were found for patients with metastatic lesions. Success rates for patients with a thyroid remnant absorbed dose of 300 Gy or more ranged from 78% to 96%, while patients with metastatic lesions receiving at least 80 Gy had success rates ranging from 46% to 98%. CONCLUSIONS: While individual studies have demonstrated the importance of absorbed doses from Na[131I]I for differentiated thyroid cancer, no conclusive absorbed dose-effect relationship has been established in this review. A lack of standardization of dosimetry methodologies and follow-up criteria in the studies obscures the relationship. Large-scale observational prospective studies are required to determine the absorbed doses required for successful personalized treatments of patients with thyroid cancer with Na[131I]I.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Taprogge J, Murray I, Newbold K, et al. A Systematic Review of Absorbed Doses and Response in Patients Treated with Radioiodine for Differentiated Thyroid Cancer. Thyroid. 2025. PMID: 41342892. doi:10.1177/10507256251396454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。